Matches in SemOpenAlex for { <https://semopenalex.org/work/W2528710744> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2528710744 abstract "Abstract The homozygous expression of phenylalanine (F/F) at codon 158 of FcγRIIIa (CD16) is associated with inferior clinical responses to the anti-CD20 monoclonal antibody rituximab in patients with indolent non-Hodgkin’s lymphoma, in contrast to higher response rates observed for Waldenstrom’s macroglobulinemia patients expressing at least one valine (V/F, V/V) and follicular NHL patients who are homozygous for valine (V/V). We attempted elucidate the potential basic mechanism(s) behind these clinical observations by analyzing all the potential implications of this polymorphism among the 3 polymorphic subgroups at FcγRIIIA-158 (F/F, V/F, and V/V). We therefore used peripheral blood isolated natural killer (NK) cells from a pool of 52 unrelated healthy donors who were genotyped for FcγRIIIA-158. We evaluated allele-specific differences for FcγRIIIa gene expression by quantitative RT-PCR and demonstrated higher transcript levels among V/V (23.2 ng/mL) versus V/F (6.7 ng/mL) and F/F (6.2 ng/mL) (p<0.0001). We then determined protein levels for CD16 in the same subgroup of donors using quantitative flow cytometry. The number of CD16 receptors per NK cell was 105,947, 94,863, and 69,130 for the V/V, V/F and F/F donors, respectively and was significantly higher among donors who expressed at least one valine (V/V and V/F) versus F/F (p=0.033). We next determined rituximab binding affinity to NK cells from V/V, V/F and F/F donors following incubation at concentrations of 10–200 ug/ml, and use of an indirect competitive assay with the anti-CD16 monoclonal antibody 3G8 (Cancer Research 64:4664). Rituximab binding to NK cells was higher among donors expressing at least one valine at all concentrations evaluated, with mean rituximab binding (defined as % of inhibition of mean fluorescence intensity for 3G8) as follow: V/V (72%); V/F (53%); and FF (37%); (p=0.017). Lastly, we assessed rituximab dependent NK cell mediated cytotoxicity (ADCC) using CD20 expressing ARH-77 B-cells and observed higher levels of ADCC killing among V/V (82%) and V/F (80%) versus F/F (23%) donors at an effector: target cell ratio of 20:1. Taken together, these studies suggest that individuals who express at least one valine at FcγRIIIA-158 might have better clinical outcomes to rituximab therapy on the basis of increased FcγRIIIA-158 receptor expression, rituximab binding and ADCC mediated killing of tumor cells." @default.
- W2528710744 created "2016-10-14" @default.
- W2528710744 creator A5009613920 @default.
- W2528710744 creator A5013473678 @default.
- W2528710744 creator A5015257672 @default.
- W2528710744 creator A5015257895 @default.
- W2528710744 creator A5026121534 @default.
- W2528710744 creator A5031106919 @default.
- W2528710744 creator A5032464400 @default.
- W2528710744 creator A5038147464 @default.
- W2528710744 creator A5045183789 @default.
- W2528710744 creator A5048560248 @default.
- W2528710744 creator A5054380955 @default.
- W2528710744 creator A5073035190 @default.
- W2528710744 creator A5081299017 @default.
- W2528710744 date "2005-11-16" @default.
- W2528710744 modified "2023-09-28" @default.
- W2528710744 title "Individuals Expressing FcγRIIIA-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIA (CD16), Rituximab Binding, and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab." @default.
- W2528710744 doi "https://doi.org/10.1182/blood.v106.11.776.776" @default.
- W2528710744 hasPublicationYear "2005" @default.
- W2528710744 type Work @default.
- W2528710744 sameAs 2528710744 @default.
- W2528710744 citedByCount "3" @default.
- W2528710744 crossrefType "journal-article" @default.
- W2528710744 hasAuthorship W2528710744A5009613920 @default.
- W2528710744 hasAuthorship W2528710744A5013473678 @default.
- W2528710744 hasAuthorship W2528710744A5015257672 @default.
- W2528710744 hasAuthorship W2528710744A5015257895 @default.
- W2528710744 hasAuthorship W2528710744A5026121534 @default.
- W2528710744 hasAuthorship W2528710744A5031106919 @default.
- W2528710744 hasAuthorship W2528710744A5032464400 @default.
- W2528710744 hasAuthorship W2528710744A5038147464 @default.
- W2528710744 hasAuthorship W2528710744A5045183789 @default.
- W2528710744 hasAuthorship W2528710744A5048560248 @default.
- W2528710744 hasAuthorship W2528710744A5054380955 @default.
- W2528710744 hasAuthorship W2528710744A5073035190 @default.
- W2528710744 hasAuthorship W2528710744A5081299017 @default.
- W2528710744 hasConcept C10205521 @default.
- W2528710744 hasConcept C114684123 @default.
- W2528710744 hasConcept C153911025 @default.
- W2528710744 hasConcept C159654299 @default.
- W2528710744 hasConcept C159912055 @default.
- W2528710744 hasConcept C167672396 @default.
- W2528710744 hasConcept C203014093 @default.
- W2528710744 hasConcept C2779338263 @default.
- W2528710744 hasConcept C2780653079 @default.
- W2528710744 hasConcept C2781038049 @default.
- W2528710744 hasConcept C2781462264 @default.
- W2528710744 hasConcept C28328180 @default.
- W2528710744 hasConcept C40677261 @default.
- W2528710744 hasConcept C542903549 @default.
- W2528710744 hasConcept C54355233 @default.
- W2528710744 hasConcept C71924100 @default.
- W2528710744 hasConcept C86803240 @default.
- W2528710744 hasConcept C8891405 @default.
- W2528710744 hasConceptScore W2528710744C10205521 @default.
- W2528710744 hasConceptScore W2528710744C114684123 @default.
- W2528710744 hasConceptScore W2528710744C153911025 @default.
- W2528710744 hasConceptScore W2528710744C159654299 @default.
- W2528710744 hasConceptScore W2528710744C159912055 @default.
- W2528710744 hasConceptScore W2528710744C167672396 @default.
- W2528710744 hasConceptScore W2528710744C203014093 @default.
- W2528710744 hasConceptScore W2528710744C2779338263 @default.
- W2528710744 hasConceptScore W2528710744C2780653079 @default.
- W2528710744 hasConceptScore W2528710744C2781038049 @default.
- W2528710744 hasConceptScore W2528710744C2781462264 @default.
- W2528710744 hasConceptScore W2528710744C28328180 @default.
- W2528710744 hasConceptScore W2528710744C40677261 @default.
- W2528710744 hasConceptScore W2528710744C542903549 @default.
- W2528710744 hasConceptScore W2528710744C54355233 @default.
- W2528710744 hasConceptScore W2528710744C71924100 @default.
- W2528710744 hasConceptScore W2528710744C86803240 @default.
- W2528710744 hasConceptScore W2528710744C8891405 @default.
- W2528710744 hasLocation W25287107441 @default.
- W2528710744 hasOpenAccess W2528710744 @default.
- W2528710744 hasPrimaryLocation W25287107441 @default.
- W2528710744 hasRelatedWork W1490375900 @default.
- W2528710744 hasRelatedWork W1494518451 @default.
- W2528710744 hasRelatedWork W1965962344 @default.
- W2528710744 hasRelatedWork W2034881692 @default.
- W2528710744 hasRelatedWork W2065298785 @default.
- W2528710744 hasRelatedWork W2160264356 @default.
- W2528710744 hasRelatedWork W2183749793 @default.
- W2528710744 hasRelatedWork W2587941327 @default.
- W2528710744 hasRelatedWork W2607497130 @default.
- W2528710744 hasRelatedWork W3168384115 @default.
- W2528710744 isParatext "false" @default.
- W2528710744 isRetracted "false" @default.
- W2528710744 magId "2528710744" @default.
- W2528710744 workType "article" @default.